



Secukinumab

Revised: December 3, 2018.

CASRN: 1229022-83-6

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of secukinumab during breastfeeding. Because secukinumab is a large protein molecule with a molecular weight of 151,000, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, secukinumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Psoriasis) Adalimumab, Etanercept, Infliximab, Phototherapy, Tretinoin

Substance Identification

Substance Name

Secukinumab

CAS Registry Number

1229022-83-6

Drug Class

Breast Feeding

Lactation

Antibodies, Monoclonal

Dermatologic Agents